Sodium–Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism

Empagliflozin is a newly developed antidiabetic drug to reduce hyperglycaemia by highly selective inhibition of sodium–glucose co-transporter 2. Hyperglycaemia is commonly seen in patients after cardiac arrest (CA) and is associated with worse outcomes. In this study, we examined the effects of empa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Yunke, Yu, Kai, Liang, Lian, Liu, Yuanshan, Song, Fengqing, Ge, Qiulin, Fang, Xiangshao, Yu, Tao, Huang, Zitong, Jiang, Longyuan, Wang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546214/
https://www.ncbi.nlm.nih.gov/pubmed/34712142
http://dx.doi.org/10.3389/fphar.2021.758080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546214/
https://www.ncbi.nlm.nih.gov/pubmed/34712142
http://dx.doi.org/10.3389/fphar.2021.758080

Ejemplares similares